文献速递免疫规划

基于gB的巨细胞病毒疫苗需全长抗原,但非成纤维细胞上中和能力降低限制豚鼠模型疫苗效力

Neutralizing antibodies to gB based CMV vaccine requires full length antigen but reduced virus neutralization on non-fibroblast cells limits vaccine efficacy in the guinea pig model.
PubMed 文献 · Vaccine · 2020-01-31

本研究评估编码豚鼠巨细胞病毒gB全长(gBwt)或缺失跨膜域截短蛋白(gBTMD)的重组缺陷腺病毒疫苗。两种疫苗均诱导高滴度抗gB抗体并在成纤维细胞上中和病毒,但在非成纤维细胞上中和较弱。gBwt疫苗可显著减少但不能阻止病毒向靶器官播散,提示全长gB抗原有望提高中和抗体滴度但未能完全预防病毒播散及可能的先天性感染。

要点

  • gBwt与gBTMD疫苗均诱导高抗gB滴度,在成纤维细胞上中和病毒。
  • 非成纤维细胞(肾上皮、胎盘滋养层)上中和较弱,依赖五聚体复合物(PC)内吞途径。
  • gBwt免疫血清中和效力约为gBTMD的2倍(肾上皮)至3倍(成纤维细胞)。

核心结论

  • 全长gB抗原有望提高中和抗体滴度,但未能完全预防病毒播散及可能的先天性感染。

研究设计与样本

  • 评估编码GPCMV gB全长(gBwt)或缺失跨膜域截短蛋白(gBTMD)的重组缺陷腺病毒疫苗。

主要发现

  • gBwt与gBTMD疫苗均诱导高抗gB滴度,在成纤维细胞上中和病毒,但在非成纤维细胞(肾上皮、胎盘滋养层)上中和较弱。
  • 抗gBwt血清中和病毒效力约为抗gBTMD血清的2倍(肾上皮细胞)至3倍(成纤维细胞)。
  • 两种gB疫苗对滋养层细胞的中和作用最弱。
  • 敲除成纤维细胞PDGFRA受体(GPKO)后病毒依赖PC途径进入,抗gB GPCMV NA50更接近上皮细胞。
  • gBwt疫苗免疫显著减少但未阻止野生型GPCMV攻击病毒向靶器官播散;体内补体耗竭对疫苗效力影响有限。

关键数值与推荐

  • 非成纤维细胞依赖病毒五聚体复合物(PC)内吞途径进入;成纤维细胞表达PDGFRA受体,经直接膜融合进入,不依赖PC。
  • 既往GPCMV gB疫苗对先天性CMV保护效力约50%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cytomegalovirus is a leading cause of congenital disease and a vaccine is a high priority. The viral gB glycoprotein is essential for infection on all cell types. The guinea pig is the only small animal model for congenital CMV (cCMV), but requires guinea pig cytomegalovirus (GPCMV). Various GPCMV gB vaccine strategies have been investigated but not with a full length protein. Previous GPCMV gB vaccines have failed to fully protect against cCMV, with approximately 50% efficacy. In an effort to define the basis of GPCMV gB based vaccine failure, we evaluated recombinant defective Ad vectors encoding GPCMV gB full length (gBwt), or truncated protein lacking transmembrane domain (gBTMD). Both candidate vaccines evoked high anti-gB titers and neutralized virus infection on fibroblast cells but had varying weaker results on non-fibroblasts (renal epithelial and placental trophoblasts). Non-fibroblast cells are dependent upon the viral pentamer complex (PC) for endocytic pathway cell entry. In contrast, fibroblasts cells that express the viral receptor platelet derived growth factor receptor alpha (PDGFRA) to enable entry by direct cell fusion independent of the PC. Anti-gBwt sera was approximately 2-fold (renal epithelial) to 3-fold (fibroblasts) more effective at neutralizing virus compared to anti-gBTMD sera. Both gB vaccines were weakest against virus neutralization on trophoblasts. Knockout of PDGFRA cell receptor on fibroblast cells (GPKO) rendered virus dependent upon the PC pathway for cell entry and anti-gB GPCMV NA50 was more similar to epithelial cells. In a gBwt vaccine protection study, vaccination of animals significantly reduced, but did not prevent dissemination of wild type GPCMV challenge virus to target organs. Depletion of complement in vivo had limited impact on vaccine efficacy. Overall, a full length gB antigen has the potential to improve neutralizing antibody titer but fails to fully prevent virus dissemination and likely congenital infection.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Choi KY, El-Hamdi NS, McGregor A, et al. Neutralizing antibodies to gB based CMV vaccine requires full length antigen but reduced virus neutralization on non-fibroblast cells limits vaccine efficacy in the guinea pig model. Vaccine. 2020. PMID: 32008881. doi:10.1016/j.vaccine.2020.01.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。